Duchenne Muscular Dystrophy Market

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Duchenne Muscular Dystrophy Market contains market size and forecasts of Duchenne Muscular Dystrophy in global, including the following market information:

• Global Duchenne Muscular Dystrophy Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global Duchenne Muscular Dystrophy Market Sales, 2017-2022, 2023-2028, (K Doses)
• Global top five Duchenne Muscular Dystrophy companies in 2021 (%)

The global Duchenne Muscular Dystrophy market was valued at 1237.8 million in 2021 and is projected to reach US$ 13240 million by 2028, at a CAGR of 40.3% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Exondys 51 Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Duchenne Muscular Dystrophy include Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco and Santhera Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Duchenne Muscular Dystrophy manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Duchenne Muscular Dystrophy Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Doses)

Global Duchenne Muscular Dystrophy Market Segment Percentages, by Type, 2021 (%)

• Exondys 51
• Emflaza
• Translarna

Global Duchenne Muscular Dystrophy Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Doses)

Global Duchenne Muscular Dystrophy Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Home Care

Global Duchenne Muscular Dystrophy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Doses)

Global Duchenne Muscular Dystrophy Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Duchenne Muscular Dystrophy revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Duchenne Muscular Dystrophy revenues share in global market, 2021 (%)
• Key companies Duchenne Muscular Dystrophy sales in global market, 2017-2022 (Estimated), (K Doses)
• Key companies Duchenne Muscular Dystrophy sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Sarepta Therapeutics
• PTC Therapeutics
• Pfizer
• Bristol-Myers Squibb
• Italfarmaco
• Santhera Pharmaceuticals